top of page
Publications
Our consultants bring over 40 years of combined experience across HEOR, HTA and statistics, and have authored peer-reviewed research in academic, government and industry settings
Selected list of publications
The work below spans therapeutic areas and evidence types. Much of our client work is confidential, so this is a selection of what we can share publicly.
Publication | Year | Output Type | Therapeutic Area | Evimed Author |
|---|---|---|---|---|
Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screening | 2026 | Journal article | Oncology | Susie Huntington |
Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy | 2025 | Journal article | Infectious disease | Susie Huntington |
Estimating the number of people who could benefit from HIV pre-exposure prophylaxis (PrEP) in England and the unmet need | 2025 | Journal article | Infectious disease | Susie Huntington |
Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework | 2025 | Conference abstract | Oncology | Chaitanyamayee Kalakota; Jiumei Gao; Necdet Gunsoy |
Worse outcomes in young women compared to men presenting with ST-elevation myocardial infarction: a 15-year statewide population-linkage cohort study | 2023 | Conference abstract | Cardiovascular | Robin Philip |
Outcomes of 46,770 patients with type 2 myocardial infarction: a statewide population-linkage study | 2023 | Conference abstract | Cardiovascular | Robin Philip |
An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia in the UK, France and Spain | 2023 | Journal article | Infectious disease | Susie Huntington |
Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation | 2023 | Journal article | Oncology | Susie Huntington |
Page 1 of 1
Let's talk about your access challenge
Tell us the indication, the markets and the deadline. A senior consultant replies — there is no account manager in between.
bottom of page